Leukopenia

04/01/1993 - "The use of CSF-primed PBPC led to a highly significant reduction in the duration of leukopenia with a white blood cell (WBC) count under 100 and 200 cells/mL, and neutrophil count under 100 and 200 cells/mL with both GM- and G-CSF primed PB progenitor cells, compared with the use of the CSF with BM or with historical controls using BM alone. "
09/01/1997 - "G-CSF significantly improved leukopenia. "
11/01/1990 - "All patients were received recombinant human granulocyte colony stimulating factor (rhG-CSF) at a dose of 300 micrograms/m2/day and which was effective for shortening the duration of leukopenia. "
04/01/1996 - "Our results reveal that G-CSF is safe and effective in the treatment of radiation-induced leukopenia regardless of the mode of application. "
03/01/2011 - "G-CSF improved severity and duration of leukopenia. "

04/01/2014 - "Our study suggests that rhG-CSF recovered metabolism in immune cells, suppressed in vivo immune defense, and attenuated immune cell proliferation in a cyclophosphamide induced leukopenia model. "
06/01/2013 - "The aim of the study is to investigate the effect of recombinant Ganoderma lucidum immunoregulatory protein (rLZ-8) on mouse models of cyclophosphamide-induced leukopenia, which we have established with both single-phase and multi-phase administration methods. "
01/01/1987 - "Previously untreated patients experienced leukopenia of less than 2,000 WBC/microliter at a significantly higher rate (53% versus 14%) than a similar patient population receiving oral cyclophosphamide as a single agent in the prior CALGB trial. "
10/01/2015 - "To investigate effective doses of cyclophosphamide (CTX) for establishment of leukopenia model in ICR mouse. "
04/01/2014 - "A cyclophosphamide leukopenia model was established in C57BL/6 mice, which were randomly divided into a normal control group (CK), a cyclophosphamide model group (CY) and a rhG-CSF treatment group (rhG-CSF). "

01/01/2003 - "Leukopenia and remission during azathioprine treatment."
10/01/1996 - "Mild leukopenia developed which improved after azathioprine reduction, and no further side-effects were noted. "
01/01/2008 - "A single study addressed the use of azathioprine (AZA) after three months of CPA therapy, showing no difference in outcome except for significantly less leukopenia in patients on AZA. "
06/01/2011 - "Myelotoxicity is a well-known adverse effect of azathioprine, leading mainly to leukopenia. "
01/01/2011 - "Patients with leukopenia due to azathioprine were no more likely to have abnormal TPMT enzyme levels than those without leukopenia (P=1.0). "

06/01/1988 - "[Enzyme immunoassay studies on drug specific antibodies in sera from patients with drug-induced immune leukocytopenia]."
11/28/1966 - "[Study of the fixation of antibodies to bone marrow cells in autoimmune leukopenia]."
07/01/2013 - "After multivariable adjustment, DLE in SLE was significantly associated with photosensitivity (odds ratio [OR] 1.63), leukopenia (OR 1.55), and anti-Smith antibodies (OR 2.41). "
09/01/2012 - "Higher mean titers of anti-Ro52 antibodies were associated with severe scintigraphic involvement, positive salivary gland biopsy, parotid enlargement, anaemia, leukopenia and RF. "
03/01/2007 - "Donors of blood products causing even mild pulmonary reactions or leukopenia should be tested for neutrophil-specific antibodies."

06/01/2008 - "Two patients developed mild leukopenia (1 case) or a slight increase in serum creatinine levels (1 case), which promptly normalized after KClO4 withdrawal. "
03/01/1999 - "No significant difference was observed between immunosuppressive protocols in serum creatinine level or incidence of leukopenia requiring medical therapy during the first year posttransplantation. "
07/01/1996 - "A multivariate analysis using the logistic regression method showed that only raised creatinine level was an independent predictor for grade 4 leukopenia (P = 0.049). "
07/01/2010 - "Eligible studies were randomized controlled trials comparing MMF with CYC with 1 of following outcomes: complete remission, complete/partial remission, infection, leukopenia, GI symptoms, serum creatinine, 24-hour urine protein, and urine albumin. "
06/15/1988 - "Patients who cleared MTX rapidly (MTX less than or equal to 2 X 10(-6) mol/l at 48 hours) rarely sustained leukopenia, creatinine elevation, or skin rash. "

01/01/2013 - "AGAF was evaluated to ease the leukopenia in CT26-colon-cancer-bearing mice treated with 5-fluorouracil (5-FU). "
01/01/2012 - "Leukopenia was observed after 5-FU treatment, but this effect was not seen with trachylobane-360 treatment. "
07/01/2011 - "Hematological analysis showed leukopenia after 5-FU treatment, but this effect was prevented when 5-FU was combined with PHT. "
05/01/2011 - "The association between ATV 5 mg/kg and 5-FU decreased the survival rate, amplified the leukopenia of animals, increased transaminase serum levels and caused liver lesions. "
01/01/2003 - "Leukopenia and hepatic toxicity were more frequent in patients receiving 5FU/Lev as compared with those receiving 5FU (respectively, p = 0.003 and p = 0.039), whereas other toxicities were equivalent and mild in both arms. "

01/01/2013 - "Nonsurvivors were immunosuppressed with leukopenia and markedly reduced tumor necrosis factor-α production capacity compared with outpatient control subjects (n = 21, p < 0.0001) and to ICU survivors (p < 0.0001). "
07/01/2006 - "The TNF-alpha c-index in all 7 patients was reduced to less than 0.3 until leukopenia appeared. "
09/04/2001 - "Both inhibition of TNF-alpha production by leukocytopenia and treatment with anti-rat TNF-alpha antibody produced effects similar to those induced by APC. "
02/15/1998 - "The induction of leukocytopenia had the same effect as APC, in that it significantly reduced motor disturbances, tissue levels of TNF-alpha, and neutrophil accumulation in the animals subjected to compressive SCI. These findings suggest that in SCI, APC reduces motor disturbances primarily by reducing the amount of TNF-alpha at the site of injury, thus inhibiting neutrophil accumulation and the resultant damage to the endothelial cells."
11/01/1995 - "This latter lethal phase, characterized by prolonged leukopenia, was blocked in a dose-dependent manner by tumor necrosis factor monoclonal antibody. "

10/01/1997 - "Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: a randomized, controlled clinical study."
09/01/1992 - "In conclusion, the results of this study indicate that GM-CSF given intermittently improves leukopenia in some patients with MDS. "
01/01/2012 - "Because of the severe leukopenia, granulocyte-macrophage colony-stimulating factor (GM-CSF) was administered until the white blood cell count significantly increased. "
07/01/2008 - "We sought to test two concepts: that nanoparticles can be used for in vivo gene delivery and that canine granulocyte-macrophage colony-stimulating factor (GM-CSF)/nanoparticles can have possibility to be used to treat transient (acute) canine leukopenia. "
04/01/2002 - "Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. "

07/01/2004 - "The purpose of this study was to assess the relation between clinical response, 6-mercaptopurine metabolite levels, relative leukopenia, and drug dose. "
08/01/1994 - "In only five patients did the leukopenia prompt a change in 6-mercaptopurine dose. "
03/01/1994 - "1) to determine the frequency of induced leukopenia in patients with refractory Crohn's disease treated with 6-Mercaptopurine (6-MP). "
02/01/2004 - "Prolonged remission of severe Crohn's disease after fever and leukopenia caused by 6-mercaptopurine."
08/01/2006 - "Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease."

01/01/2011 - "The pooled results from the four trials of Huachansu showed statistically significant difference for the improvement of leukopenia, but no significant difference for the improvement of adverse events in the digestive system or rate of short-term remission. "
01/01/2010 - "The pooled results from the four trials of Huachansu showed statistically significant difference for the improvement of leukopenia, but no significant difference for the improvement of adverse events in the digestive system or rate of short-term remission. "
01/01/2013 - "The pooled results from the four injected TCMHs, Huachansu, Aidi, Fufangkushen, and Shenqifuzheng showed statistically significant differences for the improvement of leukopenia, but no significant difference in the rate of short-term remission. "
01/01/2013 - "Limited, weak evidence showed that Huachansu, Aidi, Fufangkushen, and Shenqifuzheng improved leukopenia when used together with chemotherapy; and Huachansu, Aidi, and Fufangkushen were of benefit for adverse events in the digestive system caused by chemotherapy. "
01/01/2011 - "Limited and weak evidence showed that Huachansu, when used together with chemotherapy, improved leukopenia caused by chemotherapy, but did not improve rate of short-term remission. "

09/01/1997 - "Toxicity was not significantly different in the two groups, with the exception of leukopenia: DES chemotherapy was significantly more myelotoxic than the standard treatment, which resulted in a significant reduction in the actual dose intensity. "
01/01/2013 - "Apart from 23 trials of four different kinds of TCMHs, we could not pool the results because no more than two used the same intervention or outcomes.TCMHs with or without chemotherapy, in 57 trials, showed statistically significant differences for the improvement of mortality in nine trials, quality of life in 16 trials, rate of remission in 11 trials, and leukopenia in five trials. "
12/01/1993 - "During the period of therapy, leukopenia induced by chemotherapy was less severe and was cured more rapidly in the selected chronomedication group (CMG) than in the routine medication group (RMG). "
03/01/2002 - "The results of this pilot study suggest that EPS-EPO VIIa might be effective in reducing chemotherapy-induced leukopenia. "
06/01/2013 - "This study assesses whether chemotherapy-induced leukopenia is a predictor of efficacy and whether it is associated with the survival of SCLC patients. "

07/01/1997 - "During these stages, increases in the graft size of 100-fold improved the leukocyte counts up to 30-fold and shortened the leukopenia period by 5 to 11 days, depending on the leukocyte threshold considered. "
05/15/2015 - "Leukopenia after kidney transplant increased the risk of IA among all patients (odds ratio [OR], 2.345 [95% confidence interval {CI}, 1.084-5.071]). "
04/01/2015 - "These data show that sCBT supported with TPDCD34(+) cells results in much shorter periods of post-transplant leukopenia, but the short- and long-term rates of IRM were comparable to those of sCBT, presumably because immune recovery is equally delayed in both graft types."
12/01/2010 - "Severe leukopenia developed in one patient with CMV disease who had a D+/R-kidney transplant. "
06/01/2010 - "Posttransplant leukopenia is frequently observed in renal transplant. "

01/01/1983 - "Splenectomy failed to produce leukopenia during regeneration, although a 24-35% reduction in leukocytes occurred in otherwise intact newts. "
08/01/1978 - "In contrast, the presence of leukopenia with a low percentage of hairy cells predicted a beneficial response to splenectomy. "
03/01/1983 - "We compared 21 nondiabetic, transfused recipients of first cadaver kidney grafts who underwent pre-transplant splenectomy for steroid-resistant leukopenia to 114 without steroid-resistant leukopenia. "
03/01/1983 - "Beneficial effect of pre-transplant splenectomy for leukopenia in primary cadaver kidney transplants."
11/01/1978 - "In most patients with symptoms of thrombocytopenia or leukopenia, splenectomy led to improved blood counts. "

01/01/1996 - "[Clinical study on treatment of chemo- or radiotherapy induced leukopenia with fuzheng compound]."
04/01/2012 - "During and after radiotherapy, no treatment-related complications occurred except for transient Grade 2 leukocytopenia. "
06/01/2004 - "for 5 - 7 days constantly, and additional 3 - 5 days according to leukopenia during radiotherapy. "
01/01/2004 - "After radiotherapy in both groups statistically significant leukopenia (p < 0.001) was observed. "
06/01/1999 - "We postulate that the worsened leukopenia results from the effects of concurrent radiotherapy on circulating stem cells. "

12/01/2012 - "In conclusion, 900 mg of VGC daily may not be safe as CMV prophylaxis in high-risk liver transplant recipients because of the significant 2-fold increase in the risk of CMV disease and the 1.9-fold increase in the risk of leukopenia. "
11/01/2008 - "The risk factors, natural history, and outcomes associated with leukopenia post-transplantation have not been well defined. "
11/01/2008 - "Management of leukopenia in kidney and pancreas transplant recipients."
04/01/2008 - "The incidence of leukopenia was higher among patients under VGC since day 1 of transplantation (P = .008) with maximal incidence observed among patients prescribed 900 mg/d as opposed to those on lower doses (P < .01). "
12/01/1983 - "There is a negative non-linear correlation between the duration of leukopenia following marrow transplantation and the amount of transfused nucleated cells (p = 0.01). "